Bank of America spends over $250 million annually covering GLP-1 weight loss drugs for employees, accounting for roughly 13% of its $2 billion healthcare budget, CEO Brian Moynihan told CNBC.
Der Pharmakonzern Novo Nordisk bringt seine Abnehmpille Wegovy nach Deutschland. Trotz angehobener Jahresprognose reagierten Anleger enttäuscht auf verfehlte Umsatzerwartungen und Studiendämpfer bei Nachfolgepräparaten.
Der dänische Pharmakonzern Novo Nordisk hat im zweiten Quartal einen überraschend starken Betriebsgewinn von 33,4 Milliarden Kronen erzielt und seine Gesamtjahresprognose angehoben, gestützt durch den anhaltenden Boom bei Abnehmmedikamenten.
Australia's Therapeutic Goods Administration (TGA) has warned about a "rare but severe" eye disorder, non-arteritic anterior ischaemic optic neuropathy (NAION), linked to type 2 diabetes and obesity treatments like Ozempic and Mounjaro. The warning, based on 36 reported cases, advises patients to seek urgent medical attention for sudden vision loss but not to stop treatment without consulting a doctor.
Australia's TGA has issued a safety warning for GLP-1 drugs like Ozempic, Mounjaro, and Wegovy, linking them to non-arteritic anterior ischaemic optic neuropathy (NAION), a rare eye disorder causing potential permanent vision loss. Experts advise caution but not panic, stressing consultation with prescribers.
Pennsylvania Üniversitesi araştırmacıları, Ozempic ve Wegovy gibi GLP-1 ilaçlarının saç dökülmesi riskini SGLT-2 ve DPP-4 inhibitörlerine kıyasla daha yüksek buldu. Çalışma, hızlı kilo kaybı ve besin eksikliğinin geçici saç dökülmesine yol açabileceğini belirtiyor.
Vivani Medical is developing a GLP-1 implant for long-term weight loss maintenance, potentially reducing side effects and injection fatigue. The device, an experimental semaglutide implant, aims for twice-yearly or annual administration, complementing existing GLP-1 treatments. However, it faces clinical trials, regulatory hurdles, and questions about cost and physician adoption.
Giyilebilir teknoloji şirketi WHOOP'un araştırması, zayıflama iğnesi kullananlarda kalp ritminde ek yük ve stres oluştuğunu gösterdi. Haftada 30 dakika egzersiz ve ağırlık antrenmanı bu riskleri azaltıyor.
Ozivy, fabricado pela EMS, foi incluído na Lista de Medicamentos de Referência da Anvisa. Isso permite que outros laboratórios desenvolvam versões genéricas ou similares do medicamento no futuro, que tem o mesmo princípio ativo do Ozempic.
Novo Nordisk's weight-loss drugs Wegovy and Ozempic are seeing steady sales growth in India, outpacing generic versions. This comes as the frenzy for Indian generics wanes amid a crowded market, with innovators maintaining a steadier growth trajectory.
The once-a-day Wegovy weight-loss pill, containing semaglutide, is now available in UK high street and online pharmacies for private prescription. It is not yet available on the NHS. The pill offers a needle-free alternative to the jab but requires specific administration on an empty stomach.
The once-daily Wegovy weight loss pill, containing semaglutide, is now available privately in the UK, though not yet on the NHS. It works similarly to the injectable version by mimicking a gut hormone to reduce appetite and increase fullness, requiring a BMI of 30+ or 27-30 with weight-related conditions. Strict guidelines apply for taking the pill on an empty stomach, and costs range from £99 to £199 per month.
O Ministério da Saúde anunciou um estudo para avaliar o uso da semaglutida no SUS. A substância, usada no tratamento de diabetes e obesidade, pode reduzir o apetite e levar à perda de peso. A proposta visa superar a barreira de preço, com a Novo Nordisk oferecendo um desconto de 59%.
Grupo hacker FulcrumSec alega ter roubado mais de 700 mil arquivos da Novo Nordisk, incluindo dados de pacientes e funcionários, e ameaça vender as informações após não conseguir extorquir US$ 25 milhões da empresa.
Peptídeos, promovidos como antienvelhecimento e para performance, carecem de comprovação científica e aprovação regulatória no Brasil. Especialistas alertam para riscos de uso sem orientação médica.
O reposicionamento de medicamentos, que consiste em encontrar novos usos para fármacos já existentes, tem se mostrado uma estratégia eficaz e econômica para salvar vidas, especialmente em crises de saúde como a da COVID-19. Medicamentos como a dexametasona e o baricitinibe foram reaproveitados para tratar a inflamação em pacientes com coronavírus, salvando milhares de vidas. A Comissão Europeia planeja expandir essa abordagem para a busca de tratamentos contra o câncer. Exemplos históricos incluem o raloxifeno para prevenção de câncer de mama, a talidomida para mieloma múltiplo e o Viagra (sildenafil) para disfunção erétil, originalmente desenvolvido para doenças cardiovasculares. A tendência de reaproveitamento de medicamentos levanta questões sobre seus verdadeiros prós e contras, cujas respostas podem levar anos para serem totalmente compreendidas.
The UK's MHRA has approved the first GLP-1 receptor agonist tablet, semaglutide (Wegovy), for weight loss and management. This daily pill offers a more convenient alternative to weekly injections for adults with obesity or those overweight with weight-related conditions.
The UK's MHRA has approved Wegovy, the first GLP-1 receptor agonist tablet for weight loss, making the UK the third country to authorize the pills. This expands treatment options for adults with obesity or overweight with related health conditions.
The UK has approved a pill version of the weight-loss drug Wegovy, manufactured by Novo Nordisk. This once-daily tablet, containing semaglutide, mimics a natural hormone to suppress appetite and slow digestion. While available via prescription from pharmacies soon, its NHS availability is pending expert assessment.
A pill version of the weight-loss drug Wegovy has been approved in the UK by the MHRA. Manufacturer Novo Nordisk states the once-daily tablet offers convenience over weekly injections and doesn't require refrigeration. Its availability on the NHS is pending expert assessment.
Novo Nordisk has launched its weight loss pill Wegovy in the United Arab Emirates, marking its first expansion outside the US. The drug, approved for weight management and cardiovascular risk reduction, faces increasing competition in the growing obesity drug market.
Dezessete pessoas foram presas em Salvador em uma operação contra um grupo suspeito de roubo a farmácias, tráfico de drogas e armas, e lavagem de dinheiro. A ação também cumpre mandados no Rio de Janeiro e São Paulo, com bloqueio de bens de R$ 12,5 milhões.
Novo Nordisk has launched its weight loss pill Wegovy in the United Arab Emirates, marking its first expansion outside the U.S. market. The drug's approval by the Emirates Drug Establishment follows recent competition from Eli Lilly in the growing obesity drug sector.
Starting mid-June, France will reimburse 65% of Wegovy and Mounjaro obesity treatments for eligible patients. While patients report effectiveness, high costs and strict eligibility criteria, excluding those with IMC below 35 or 40 without comorbidities, are major concerns.
